Reprotect Buffergel Phase II Data May Serve As Basis For NDA

Data from a Phase II study on the contraceptive efficacy of Reprotect's Buffergel polyacrylic acid may serve as the basis for an eventual NDA filing by the firm. A Phase II trial of the gel's efficacy in preventing pregnancy may begin within the next six months.